Vaccine type | P value | ||||
Total (N=6943) | Pfizer-BioNTech (N=3824) | Moderna (N=2620) | Adenoviral Vector/mRNA (N=499) | ||
Age at enrolment (median, IQR) | 64 (53–75) | 71 (55–78) | 61 (54–69) | 45 (31–55) | . |
Age group (N, %) | <0.0001 | ||||
18–25 | 159 (2.3) | 59 (1.5) | 64 (2.4) | 36 (7.2) | . |
25–39 | 384 (5.5) | 152 (4.0) | 62 (2.4) | 170 (34.1) | . |
40–64 | 3191 (46.0) | 1326 (34.7) | 1577 (60.2) | 288 (57.7) | . |
65–79 | 2313 (33.3) | 1557 (40.7) | 752 (28.7) | 4 (0.8) | . |
≥80 | 896 (12.9) | 730 (19.1) | 165 (6.3) | 1 (0.2) | . |
Sex (N, %) | <0.0001 | ||||
Male | 3014 (43.4) | 1841 (48.1) | 1085 (41.4) | 88 (17.6) | . |
Female | 3929 (56.6) | 1983 (51.9) | 1535 (58.6) | 411 (82.4) | . |
Risk group (N,%) | <0.0001 | ||||
Individuals at increased risk | 1599 (23.0) | 1437 (37.6) | 153 (5.8) | 9 (1.8) | . |
Healthcare workers | 590 (8.5) | 109 (2.9) | 28 (1.1) | 453 (90.8) | . |
General population | 4754 (68.5) | 2278 (59.6) | 2439 (93.1) | 37 (7.4) | . |
Ever SARS-CoV-2 PCR positive | <0.0001 | ||||
Never | 6704 (96.6) | 3718 (97.2) | 2534 (96.7) | 452 (90.6) | . |
Positive ≤6 months | 180 (2.6) | 82 (2.1) | 56 (2.1) | 42 (8.4) | . |
Positive >6 months | 59 (0.8) | 24 (0.6) | 30 (1.1) | 5 (1.0) | . |